Innovent Biologics, Inc. is set to showcase its cutting-edge research at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2024, taking place from May 31 to June 4 in Chicago, IL, U.S. The company will present approximately 20 accepted abstracts featuring clinical data from various trials involving their novel mono- and bi-specific antibodies, antibody-drug conjugates, and innovative drugs such as TYVYT® (sintilimab injection), olverembatinib, and taletrectinib.
These groundbreaking findings underscore Innovent’s commitment to advancing cancer treatment through its robust oncology pipeline. The ASCO Annual Meeting serves as a premier platform for oncology professionals worldwide to share the latest discoveries and developments in cancer research, providing Innovent with an opportunity to highlight the potential of its innovative therapies in improving patient outcomes.
